High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: a meta-analysis.

This meta-analysis indicated that high plasma/intratumoral VEGF-A level at baseline could predict poor treatment effect (depressed PFS and OS) of BEV-based chemotherapy in mCRC, although there was no correlation between intratumoral VEGF-A level and ORR following BEV-based treatment.